• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 18, 2015

View Archived Issues

Lone phase III could approve new paclitaxel behind $1.3B-plus Sorrento, Nantworks deal

Less than two weeks after disclosing an upbeat but not very specific press release about phase III bioequivalence results comparing its version of albumin-bound paclitaxel, Cynviloq, to Celgene Corp.'s marketed blockbuster Abraxane, Sorrento Therapeutics Inc.'s potential $1.3 billion-plus deal with Nantworks Inc. gained what one analyst called a "huge validation" of the candidate's potential. Read More

Circassia adds asthma pipeline, sales force via double dose of M&A

LONDON – Circassia Pharmaceuticals plc is raising £275 million (US$432 million) in a placing and open offer to fund the acquisition of two fellow respiratory specialists – Aerocrine AB, with a sales force and two commercial products, and Prosonix Ltd., which has an advanced portfolio of generic inhaled asthma drugs, the first of which is due to be approved imminently. Read More

Cortendo assembles more rare disease assets, adds $33.2M financing

Cortendo AB made clear that it's no longer a sleepy little Swedish biotech by acquiring two late-stage candidates targeting acromegaly and other endocrinology applications and tacking on another $33.2 million in a private placement. Read More

Search for painkillers comes half-circle

A genomics-based search for better drug targets for painkillers has turned up a candidate that is, in one sense, not new at all. That candidate is the nicotinic acetylcholine receptor, already the beneficiary of one failed round of drug development. Read More

Astrazeneca ramps up sequencing, companion diagnostic initiatives

LONDON – Astrazeneca plc is pushing personalized medicine and targeted therapies beyond the confines of cancer and into cardiovascular, metabolic and respiratory indications, with plans for a companion diagnostic for a phase III asthma product and a large-scale R&D tie-up with the Montreal Heart Institute to discover genetic markers with which to stratify heart disease and diabetes patients. Read More

Phoremost 'prospecting at protein level' to resolve undruggability

LONDON – "Drugging the undruggable" is the bold claim newco Phoremost Ltd. is making for its technology. The Cambridge University spinout said it can systematically identify and access intracellular targets that are undruggable using classic approaches. Read More

Financings

Sernova Corp., of Vancouver, British Columbia, completed a nonbrokered, oversubscribed private placement of approximately 8.9 million units at 18 cents apiece for gross proceeds of C$1.6 million (US$1.3 million). Read More

Stock movers

Read More

Other news to note

Celsion Corp., of Lawrenceville, N.J., said findings from a preclinical study confirming effective delivery of RNA to lung cells was summarized in an abstract in the Journal of Controlled Release. Read More

In the clinic

The Janssen unit of Johnson & Johnson, of New Brunswick, N.J., said data from an ongoing postmarketing study of once-daily factor Xa inhibitor Xarelto (rivaroxaban) in patients with nonvalvular atrial fibrillation showed the rates of major bleeding and fatal outcomes in elderly patients treated in routine clinical practice generally are consistent with those reported in phase III trials, which show a correlation between increased age and bleeding. Read More

Bench Press: BioWorld looks at translational medicine

Researchers from the British Cambridge University have shown that nearly a quarter of all genes show seasonal variations in expression levels, suggesting that the generally better health that individuals show in the summer might be due to seasonal variations in immune system function. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Kymera’s phase I data lead big week for STAT6 space

    BioWorld
    It’s a good week to be working on drugs targeting STAT6. Kymera Therapeutics Inc.’s, KT-621, the first oral STAT6 degrader candidate to enter the clinic,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe